NCT04750122View on ClinicalTrials.gov

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 28, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2026

Conditions
HER2-positive Early Breast Cancer
Interventions
DRUG

neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning

The choice of chemotherapy is based on the PTC drug sensitivity results.

Trial Locations (1)

100044

RECRUITING

Peking University People'S Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT04750122 - Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients | Biotech Hunter | Biotech Hunter